A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants

An Open-label, 3-Arm, Parallel Design Pharmacokinetic Interaction Study Between MYK-224 and Cytochrome P450 3A4 Inhibitors Itraconazole and Verapamil in Healthy Participants

The purpose of this study is to evaluate the effect of co-administration of itraconazole or verapamil on the drug levels of MYK-224 in healthy participants.

Inclusion Criteria:

• Body mass index between 18 and 30 kg/m^2, inclusive
• Healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram and routine laboratory assessments
• Adequate acoustic windows to enable accurate transthoracic echocardiographic assessment
• Left Ventricular Ejection Fraction (LVEF) ≥60% at screening and ≥55% prior to MYK-224 dosing

Exclusion Criteria:

• Any acute or chronic medical illness
• History of dizziness and/or recurrent headaches
• History of heart disease

Other protocol-defined inclusion/exclusion criteria apply